L2 Asset Management LLC bought a new position in Merck KGaA (OTCMKTS:MKGAF – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 8,861 shares of the company’s stock, valued at approximately $1,139,000.
A number of other institutional investors also recently modified their holdings of the stock. Frazier Financial Advisors LLC purchased a new position in shares of Merck KGaA during the 2nd quarter valued at $25,000. Rakuten Securities Inc. acquired a new position in shares of Merck KGaA in the second quarter worth $27,000. Solstein Capital LLC purchased a new stake in shares of Merck KGaA during the second quarter worth $33,000. Burk Holdings LLC purchased a new stake in shares of Merck KGaA during the second quarter worth $39,000. Finally, Bard Associates Inc. acquired a new stake in Merck KGaA during the second quarter valued at $60,000. Institutional investors and hedge funds own 0.10% of the company’s stock.
Merck KGaA Stock Performance
Shares of OTCMKTS MKGAF opened at $163.45 on Tuesday. The business’s 50-day moving average price is $162.78 and its two-hundred day moving average price is $148.59. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.31 and a quick ratio of 0.84. Merck KGaA has a one year low of $116.68 and a one year high of $175.56. The company has a market capitalization of $21.12 billion, a P/E ratio of 24.95 and a beta of 0.96.
Merck KGaA Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Further Reading
- Five stocks we like better than Merck KGaA
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
